Treatment of low-risk non-muscle-invasive bladder cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F12%3A8397" target="_blank" >RIV/00064203:_____/12:8397 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/12:8397

Výsledek na webu

<a href="http://www.touchurology.com/articles/treatment-low-risk-non-muscle-invasive-bladder-cancer" target="_blank" >http://www.touchurology.com/articles/treatment-low-risk-non-muscle-invasive-bladder-cancer</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Treatment of low-risk non-muscle-invasive bladder cancer

Popis výsledku v původním jazyce

Low-risk non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 50 % of newly diagnosed bladder cancer. It is defined by the European Organisation for Research and Treatment of Cancer (EORTC) risk tables and is characterised by low risk ofboth recurrence and progression. Transurethral resection of the bladder (TURB) is the crucial step in its management. The aim is to eradicate all tumours and establish an accurate diagnosis. Narrow-band imaging and fluorescence cystoscopy (photodynamicdiagnosis [PDD]) detect more lesions. PDD also improves recurrence-free survival. Single immediate intravesical instillation after TURB is the standard of care in low-risk NMIBC since it prolongs time to recurrence. Some patients with small papillary recurrent low risk tumours may be observed or treated by office fulguration. All patients should be followed by regular cystoscopies. Results of the first cystoscopy three months after TURB is a surrogate marker for patient's prognosis

Název v anglickém jazyce

Treatment of low-risk non-muscle-invasive bladder cancer

Popis výsledku anglicky

Low-risk non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 50 % of newly diagnosed bladder cancer. It is defined by the European Organisation for Research and Treatment of Cancer (EORTC) risk tables and is characterised by low risk ofboth recurrence and progression. Transurethral resection of the bladder (TURB) is the crucial step in its management. The aim is to eradicate all tumours and establish an accurate diagnosis. Narrow-band imaging and fluorescence cystoscopy (photodynamicdiagnosis [PDD]) detect more lesions. PDD also improves recurrence-free survival. Single immediate intravesical instillation after TURB is the standard of care in low-risk NMIBC since it prolongs time to recurrence. Some patients with small papillary recurrent low risk tumours may be observed or treated by office fulguration. All patients should be followed by regular cystoscopies. Results of the first cystoscopy three months after TURB is a surrogate marker for patient's prognosis

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Urological Review

ISSN

1758-3829

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

24-28

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—